The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease. One study is analyzing fenofibrate, which is typically used for cholesterol management, to evaluate how it protects against retinopathy worsening, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Transcript
What trials are ongoing in the DRCR Retina Network that you want to highlight?
We're very interested in understanding, now that we have good treatments for late-stage disease—in terms of proliferative diabetic retinopathy and diabetic macular edema—how do we develop preventive strategies? One of the studies that is currently up and recruiting is a study looking at fenofibrate use for prevention of retinopathy worsening in early-stage diabetic retinopathy. There are a couple of large cardiovascular studies that have suggested that patients on fenofibrate, which has been typically used for cholesterol management—it's been around for decades, and it's pretty well tolerated, it's cheap, because it's off patent, so it's readily available—these studies have suggested that patients on fenofibrate seem to be protected against retinopathy worsening.
Nonetheless, in general, physicians have not used fenofibrate as first-line treatment for diabetic retinopathy, you know, early-stage disease. We're starting a study that will follow patients for 4 years—randomize them to fenofibrate vs placebo. There are a number of studies that are also ongoing within that study looking at how we look at visual function in these patients through contrast sensitivity, through visual fields, and development of imaging biomarkers of disease progression.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen